LXRX FY 2024 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M+2481.5% YoY

Gross Profit

$30M98.0% margin

Operating Income

-$197M-634.2% margin

Net Income

-$200M-644.8% margin

EPS (Diluted)

$-0.63

Cash Flow

Operating Cash Flow

-$179M

Free Cash Flow

-$180M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$298M

Total Liabilities

$152M

Stockholders' Equity

$146M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$1M	+2481.5%
Gross Profit	$30M	-$58M	+152.7%
Operating Income	-$197M	-$172M	-14.8%
Net Income	-$200M	-$177M	-13.1%